Building on these insights, we explored the use of VIT-2763 (Vamifeport, VIT), a novel oral FPN inhibitor currently under development for the treatment of hemoglobinopathies such as sickle cell anemia and β-thalassemia [14,15,16,17,18], and is undergoing phase 1 trials in healthy volunteers [19]. Here, SLC40A1 is linked to sickle cell disease.